2021 CMSC Annual Meeting

Tag: 2

Poster-Disease-modifying Therapy

Efficacy and Safety of Eculizumab in Patients with Neuromyelitis Optica Spectrum Disorder Previously Treated with Rituximab: Findings from Prevent

Background: In PREVENT, eculizumab was associated with a significant reduction in relapse risk versus placebo and was well tolerated. In...

Read More

Poster-Disease-modifying Therapy

Real-Life Experience with Ocrelizumab in Older Patients at an Academic MS Center

Background: Ocrelizumab (OCR) is a B-Cell depleting humanized monoclonal antibody FDA-approved for treatment of relapsing remitting...

Read More

Poster-Complementary and Alternative Therapies

Evaluation of a 6 Week Integrative Medicine Workshop Series on Quality of Life, Self-Efficacy and Wellness in MS

Background: MS care provided in a comprehensive MS center improves outcomes. Well-established MS centers struggle to include complementary...

Read More

Platform-Psychosocial

Association between Cognition and Social Role Participation Among Patients with Multiple Sclerosis

Background: Multiple sclerosis (MS), a relapsing and progressive demyelinating disease of the central nervous system, results in impaired...

Read More